Skip to main content
Clinical Trials/NCT04402892
NCT04402892
Unknown
Not Applicable

SARS-CoV-2 Specific Memory B and T- CD4+ Cells

Assistance Publique - Hôpitaux de Paris0 sites60 target enrollmentJune 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID-19
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
60
Primary Endpoint
Immunological memory: resolution of COVID-19 after SARS-CoV2 infection.
Last Updated
5 years ago

Overview

Brief Summary

The current pandemic caused by the newly identified coronavirus responsible for COVID-19 is a major threat to our populations and societies.

Hypothesis/Objective The acquisition of protective immunity at the level of the individual, either through vaccination or natural resolution of the infection, progressively leads at the level of the population to the reduction of the fraction of the population that can be productively infected and transmit the virus, hence, leading to the diminution of the rate of transmission, a phenomenon called herd immunity. Herd immunity was proposed as a strategy to control the infection. However, it remains difficult to model group immunity given the limited knowledge of the interaction between the host immune system with the virus, whose capacity to evolve in face of a neutralizing response is also not known. It is therefore important to acquire a better knowledge of the immunological memory that ensures the resolution of COVID-19 after SARS-CoV2 infection.

Method To study single-cell B and T memory cells specific for the anti-SARS-CoV-2 response and characterize somatic mutations of immunoglobulin genes and TCR, in hospitalized and symptomatic patients and in patients cured of SARS-CoV-2.

Registry
clinicaltrials.gov
Start Date
June 1, 2020
End Date
March 1, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients who have recovered from CoV-2-SARS
  • Adult patient (≥ 18 years old) with a positive SARS-CoV-2 PCR.
  • Adult patient (≥ 18 years old) who has recovered from SARS-CoV-2 i.e. has been free of clinical symptoms for more than 15 days and has not been hospitalized and for less than 6 weeks.
  • Patient affiliated to a social security scheme.
  • Patients hospitalized for SARS-CoV-2
  • Adult patient (≥ 18 years old) with a positive SARS-CoV-2 PCR.
  • Adult patient (≥ 18 years old) with clinical symptoms for more than 3 days and hospitalized.

Exclusion Criteria

  • Refusal of the patient to participate in the study.
  • Patient under guardianship / curatorship

Outcomes

Primary Outcomes

Immunological memory: resolution of COVID-19 after SARS-CoV2 infection.

Time Frame: 5 years

Biological blood collection: Blood samples taken in the course of the research will be part of a biological collection To study single-cell B and T memory cells specific for the anti-SARS-CoV-2 response and characterize somatic mutations of immunoglobulin genes and TCR, in hospitalized and symptomatic patients and in patients cured of SARS-CoV-2.

Similar Trials